Summit Therapeutics Reports Another Quarter of Spending Someone Else's Money While Waiting for November
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Summit typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-07-23 | +$0.24 (+1.63%) | $0.65 (4.41%) | -$1.32 (-8.81%) | $1.22 (8.14%) |
| 2026-04-30 | +$0.63 (+3.02%) | $1.53 (7.34%) | -$5.35 (-24.91%) | $1.67 (7.78%) |
| 2026-02-23 | +$0.15 (+0.94%) | $0.55 (3.45%) | +$0.03 (+0.19%) | $1.30 (8.08%) |
| 2025-10-20 | -$0.95 (-4.55%) | $2.90 (13.82%) | -$1.30 (-6.46%) | $1.40 (6.99%) |
| 2025-08-11 | -$0.41 (-1.43%) | $1.78 (6.21%) | -$2.57 (-9.08%) | $3.49 (12.35%) |
| 2025-05-01 | +$0.55 (+2.28%) | $1.79 (7.42%) | +$3.23 (+13.09%) | $4.18 (16.94%) |
| 2025-02-24 | -$3.28 (-14.83%) | $4.19 (18.94%) | -$0.73 (-3.87%) | $1.50 (7.96%) |
| 2024-10-30 | -$3.18 (-14.57%) | $2.58 (11.82%) | -$0.06 (-0.32%) | $1.33 (7.10%) |
| Avg Abs Move | 5.41% | 9.18% | 8.34% | 9.42% |
Summit exhibits high volatility around earnings, with an average absolute Day 0 move of 5.41% and Day +1 move of 8.34%. The stock has shown particularly dramatic reactions in recent quarters, including a 25% decline on Day +1 following the April 2026 report and a 13% gain on Day +1 after May 2025 earnings.
The most recent July 2026 report was relatively muted, with just a 1.63% gain on Day 0 followed by an 8.81% decline on Day +1. However, the historical pattern shows Day +1 moves frequently exceed 10% in either direction, with four of the past eight reports producing Day +1 moves of 6% or greater. The average intraday range of 9.18% on Day 0 and 9.42% on Day +1 underscores the stock's tendency for wide swings during earnings periods.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 10/30/26 (DTE 7) |
| Expected Move | $1.62 (10.51%) |
| Expected Range | $13.83 to $17.07 |
| Implied Volatility | 117.58% |
The options market is pricing a 10.51% move by October 30, which is moderately above the historical Day 0 average of 5.41% but below the Day +1 average of 8.34%. This suggests options traders are anticipating volatility in line with recent history, though not at the extreme levels seen in some prior quarters.
Part 3: What Analysts Are Saying
Analysts maintain a strongly bullish stance on Summit Therapeutics. The stock carries an average recommendation of 4.22 out of 5.0, with 11 Strong Buy ratings, 0 Moderate Buys, 7 Holds, and no Sell ratings among 18 analysts covering the stock.
The consensus price target stands at $29.14, implying 88% upside from the current price of $15.47. Price targets range from a low of $11.90 to a high of $43.00, reflecting divergent views on the commercial potential of ivonescimab but with the majority of analysts seeing substantial appreciation potential.
Analyst sentiment has remained unchanged over the past month, with the rating distribution holding steady at 11 Strong Buys and 7 Holds. The stability in ratings suggests analysts are maintaining conviction in their bullish thesis heading into both the earnings report and the critical November 14 FDA decision. Over the past 90 days, the stock has seen 3 upgrades and 0 downgrades, indicating improving sentiment as key catalysts approach.
Part 4: Technical Picture
Summit enters earnings with deteriorating technical momentum. The Barchart Technical Opinion currently shows a Sell signal at 24%, improving from last week's 40% Sell but significantly weaker than last month's 8% Buy reading. This shift reflects the stock's recent pullback from higher levels.
Timeframe Analysis:
- Short-term (50% Buy): Neutral-to-positive signal suggests near-term momentum has stabilized after recent weakness
- Medium-term (50% Sell): Moderate sell signal indicates consolidation or downtrend in the intermediate timeframe
- Long-term (50% Sell): Moderate sell signal reflects pressure in the longer-term trend structure
Trend Characteristics: The signal strength is rated Minimum with a Weakening direction, indicating the technical setup is fragile and losing momentum heading into the earnings event.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $15.70 | 50-Day MA | $15.79 |
| 10-Day MA | $15.63 | 100-Day MA | $15.03 |
| 20-Day MA | $16.29 | 200-Day MA | $16.24 |
The stock is trading at $15.47, positioned below its 5-day ($15.70), 10-day ($15.63), 20-day ($16.29), 50-day ($15.79), and 200-day ($16.24) moving averages, though it remains above the 100-day average of $15.03. This configuration shows the stock is struggling with near-term resistance levels and trading in the lower half of its recent range. The 52-week range of $12.07 to $29.23 places the current price roughly 25% of the way up from the low, suggesting significant room for upside if catalysts materialize but also reflecting substantial downside risk if news disappoints. The overall technical setup is cautionary heading into earnings, with weak momentum and the stock trading below most key moving averages despite the proximity of major catalysts.